Global Blood Therapeutics, Inc. (GBT) financial statements (2020 and earlier)

Company profile

Business Address 171 OYSTER POINT BLVD, SUITE 300
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments268275315147149
Cash and cash equivalents26827519892149
Short-term investments  11655 
Prepaid expense 6421
Other current assets 2611
Other undisclosed current assets348202   
Total current assets:616486324150151
Noncurrent Assets
Operating lease, right-of-use asset14
Property, plant and equipment14151722
Long-term investments and receivables  1550 
Long-term investments  1550 
Restricted cash and investments22100
Other noncurrent assets100  
Other undisclosed noncurrent assets80114   
Total noncurrent assets:11213232532
TOTAL ASSETS:727618357202153
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4033261510
Accounts payable76743
Accrued liabilities22171054
Employee-related liabilities1010952
Other liabilities11011
Total current liabilities:4134261611
Noncurrent Liabilities
Long-term debt and lease obligation24    
Operating lease, liability24
Liabilities, other than long-term debt4111212
Other liabilities4111212
Total noncurrent liabilities:28111212
Total liabilities:6945381612
Stockholders' equity
Stockholders' equity attributable to parent658573319186141
Common stock00000
Additional paid in capital1,3001,045617367239
Accumulated other comprehensive income (loss)1(0)(0)(0) 
Accumulated deficit(643)(472)(298)(181)(98)
Total stockholders' equity:658573319186141
TOTAL LIABILITIES AND EQUITY:727618357202153

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Gross profit:    0
Operating expenses(234)(183)(119)(83)(46)
Other undisclosed operating loss    (0)
Operating loss:(234)(183)(119)(83)(46)
Nonoperating income11   0
Investment income, nonoperating    0
Other nonoperating income11    
Other undisclosed loss from continuing operations before equity method investments, income taxes(6)    
Loss from continuing operations before equity method investments, income taxes:(229)(183)(119)(83)(46)
Other undisclosed income from continuing operations before income taxes9921 
Net loss:(220)(174)(117)(82)(46)
Other undisclosed net loss attributable to parent(0)(0)   
Net loss attributable to parent:(220)(174)(117)(82)(46)
Other undisclosed net loss available to common stockholders, basic    (4)
Net loss available to common stockholders, diluted:(220)(174)(117)(82)(51)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(220)(174)(117)(82)(46)
Comprehensive loss:(220)(174)(117)(82)(46)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent10(0)(0) 
Comprehensive loss, net of tax, attributable to parent:(219)(174)(117)(83)(46)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: